Hepatitis C Treatment Guidelines

(AASLD)
Genotype

1, 2, 3
Without Cirrhosis

1, 2, 3
Compensated Cirrhosis

4, 5, 6

Treatment Nave

Peg IFN +
Ribavirin
Exposure

Daclatasvir +
Sofosbuvir
(12 weeks)

Daclatasvir +
Sofosbuvir
(12 weeks)

Daclatasvir +
Sofosbuvir
Ribavirin (24
weeks)

Daclatasvir +
Sofosbuvir
+ Ribavirin (24
weeks)

(No Ribavirin for Geno

2)

(No Ribavirin for Geno

2)

Ledipasvir +
Sofosbuvir
(12 weeks)

Ledipasvir = 90mg OD
Sofosbuvir = 400mg OD
Daclatasvir = 60mg OD
Ribavirin = Weight based BD

Sofosbuvir +
Ribavirin Peg
IFN Exposure
Ledipasvir +
Sofosbuvir + Ribavirin
(12 weeks, Geno 1)
Daclatasvir +
Sofosbuvir + Ribavirin
(24 weeks for Geno 2,
3)
Ledipasvir +
Sofosbuvir + Ribavirin
(24 weeks, Geno 1)
Daclatasvir +
Sofosbuvir + Ribavirin
(24 weeks for Geno 2,
3)

Ledipasvir +
Sofosbuvir
(12 weeks, Geno 4, 5,
6)
?
(24 weeks if
compensated
Cirrhosis in Geno 4)